Venaxis, Inc.
 (APPY)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Jul. 15, 2013, 8:40 AM

    Venaxis (APPY) says the external Data & Safety Monitoring Board created for the trial of the company's APPY1 Test has recommended continuing the study based on two futility analyses that were carried out on 579 patients. The trial will enroll a total of 2,000 patients for the APPY1 Test, which identifies patients who are at low risk of appendicitis. Shares are -5.1%, possibly because Venaxis expects to complete recruitment by the end of 2013 rather than in August, as previously forecast, and file for FDA clearance in Q1 2014. (PR)

    | Jul. 15, 2013, 8:40 AM
  • May 24, 2013, 11:52 AM

    Venaxis (APPY -5%) slips today after pricing its 10M shares and related warrants to purchase 3.5M shares at a combined public price of $1.25 per share with an exercise price of $1.36. The offering is expected to close on May 30. Venaxis should realize approximately $11.1M in net proceeds from the sale, for which it intends to use primarily for funding of further clinical development and seeking FDA clearance for APPY1, as well as for initial commercialization of the drug in the U.S. and the E.U.

    | May 24, 2013, 11:52 AM
  • May 24, 2013, 9:10 AM
    Premarket gainers: BLOX +17%. IOC +15%. YGE +13%. P +11%. MRVL +5%.
    Losers: DF -52%. SHLD -16%. AVEO -15%. RSOL -13%. TITN -11%. APPY -7%. ANF -7%. CRM -5%.
    | May 24, 2013, 9:10 AM | 2 Comments
  • Mar. 26, 2013, 8:09 PM

    Venaxis Inc. (APPY) climbs in the post-trade session after providing an update on its clinical and commercial activities, reporting in its 10-K that it continues to enroll patients into its ongoing clinical study of APPY1, and it anticipates completing the study and potentially filing with the FDA for regulatory clearance by year end. Read more on its Business Update Conference Call Here: Business Update Transcript. Shares +5% AH.

    | Mar. 26, 2013, 8:09 PM
  • Feb. 25, 2013, 12:53 PM
    Midday top 10 gainers: ENMD +26%. OBCI +25%. GALT +19%. APPY +15%. NTWK +12%. BKS +12%. ZNGA +11%. HXM +10%. MGN +10%. CMGE +9%.
    Midday top 10 losers: AFFY -86%. CEDC -55%. DVAX -33%. GGS -31%. GMXR -24%. TROV -17%. EMITF -16%. ESI -14%. FRO -14%. XRSC -13%.
    | Feb. 25, 2013, 12:53 PM
  • Feb. 25, 2013, 10:43 AM

    Shares of beaten-down Venaxis (APPY +18.2%) are soaring today after Canaccord upgraded the stock to Buy and nearly tripled its price target to $7.00 from $2.50. The firm says that APPY's pursuit of a blood test to identify those at low risk for appendicitis is compelling, considering that appendicitis is the most-common non-traumatic childhood surgical disease. FDA approval could come before mid-2014 and the U.S. market alone could be nearly $700M.

    | Feb. 25, 2013, 10:43 AM
  • Feb. 7, 2013, 9:14 AM
    Premarket gainers: OXGN +31%. SUTR +29%. DV +18%. BIOL +9%. AAP +9%. ORLY +9%. APPY +7%. LF +6%.
    Losers: AKAM -18%. TQNT -11%. ARAY -9%. ANN -9%. GMCR -9%. NXST -6%. BBEP -6%. MWW -6%. BG -5%. ATML -5%.
    | Feb. 7, 2013, 9:14 AM
  • Jan. 8, 2013, 1:45 PM

    Venaxis (APPY -9.6%) slips today, despite its announcement late yesterday that European regulators have approved the company's blood-based appendicitis test APPY1. Initial sales are slated to begin during Q1 in key territories, including the UK, Italy, France, Germany and Benelux countries. The company expects to announce agreements with top EU distributors beginning in the first quarter 2013.

    | Jan. 8, 2013, 1:45 PM
  • Jan. 8, 2013, 9:10 AM
    Premarket gainers: PERI +19%. STSI +16%. CTIC +8%. PPHM +5%.
    Losers: GME -10%. APPY -6%. CY -6%. CLMT -5%.
    | Jan. 8, 2013, 9:10 AM
  • Dec. 21, 2012, 9:10 AM
    Premarket gainers: HALO +19%. CEMI +17%. ASCA +17%. APPY +14%. RHT +5%. PNK +5%. SHP +5%.
    Losers: ECTE -18%. RIMM -14%. ALU -7%.
    | Dec. 21, 2012, 9:10 AM | 1 Comment
  • Nov. 15, 2012, 10:30 AM

    AspenBio Pharma (APPY -13.8%) falls after pricing its previously announced secondary offering of 1.5M shares at $2.10 each, a 15% discount to Wednesday's close. The diagnostic-product developer has a 7.7M share float outstanding at the beginning of November.

    | Nov. 15, 2012, 10:30 AM
  • Nov. 15, 2012, 9:10 AM
    Premarket gainers: BXG +68%. ACRX +31%. DANG +14%. NTAP +12%. ELOQ +12%. AMRN +7%. LPH +7%.
    Losers: VELT -27%. DMND -23%. APPY -17%. TDG -6%. AKS -5%. DRYS -5%. VGR -5%. NGLS -5%.
    | Nov. 15, 2012, 9:10 AM
  • Nov. 14, 2012, 5:08 PM

    AspenBio Pharma (APPY) announces a secondary offering for an undisclosed amount of its common stock. The company intends to use the net proceeds for general corporate purposes, which includes conducting a clinical trial for its blood-based appendicitis test, and for working capital purposes. Aegis Capital is acting as the sole book-running manager for the offering. Shares -8.5% AH.

    | Nov. 14, 2012, 5:08 PM
  • Oct. 16, 2012, 12:45 PM
    Midday top 10 gainers: NOOF +54%. DSTI +37%. INVE +31%. BCOM +17%. PAMT +16%. PRXI +16%. TRT +16.%. APPY +13%. ARL +12%. RLGT +11%. Top 10 Losers: AONE -75%. RATE -24%. OSG -22%. KFS -19%. ISIS -18%. VRML -18%. CLWR -15%. OCZ -11%. CMRE -11%. VIMC -10%.
    | Oct. 16, 2012, 12:45 PM | 1 Comment
  • Oct. 9, 2012, 12:45 PM
    Midday top 10 gainers: BSDM +73%. ALDA.PK +28%. APPY +22%. RITT +19%. OTT +17%. TRT +17%. HOLL +15%. PRPH +13%. PBM +13%. BIOF +12%.
    Top 10 Losers: VDSI -23%. MGT -22%. EW -19%. THM -19%. GLUU -18%. PVA -16%. PAMT -15%. ANGO -13%. VRNG -11%. UNIS -10%.
    | Oct. 9, 2012, 12:45 PM | 1 Comment
  • Sep. 27, 2012, 12:45 PM
    Midday top 10 gainers: CTC +71.53%. ROYL +31.38%. APPY +18.48%. TPX +16.5%. ULTR +15.6%. WZE +13.09%. STRM +12.7%. IGLD +12.62%. PNX +11.22%. PRAN +11.17%.
    Top 10 Losers: PPHM -35.54%. CAFI -12.94%. SYUT -10.64%. CPHD -9.58%. MTE -9.02%. MITK -8.92%. CHYR -8%. CYTX -7.76%. FUL -7.37%. UBNT -7.07%.
    | Sep. 27, 2012, 12:45 PM
Company Description
Venaxis Inc is engaged in the development and commercialization of products that address unmet diagnostic and therapeutic needs.